Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Keio University Research: Ancient antiviral response could help treat cancer
  • USA - English


News provided by

Keio University (JAPAN)

Nov 09, 2017, 16:00 ET

Share this article

Share toX

Share this article

Share toX

Three-dimensional organoids derived from human cholangiosarcoma tumor cells. © 2017 Yoshimasa Saito, Keio University.
Three-dimensional organoids derived from human cholangiosarcoma tumor cells. © 2017 Yoshimasa Saito, Keio University.

TOKYO (PRWEB UK) 10 November 2017 -- Keio University publishes its October 2017 issue of Keio University Research Highlights. This issue includes updates of recent research by Keio University scientists on ‘ancient antiviral response could help treat cancer’ and ‘digital 3D-fabrication technology for nursing and healthcare’.

Keio Research Highlights website
https://research-highlights.keio.ac.jp/

Ancient antiviral response could help treat cancer
A class of drugs can harness the power of the body’s immune system to fight diverse tumors

Organoids are budding, cyst-like structures that closely recapitulate the properties of the original tumors

Post this

https://research-highlights.keio.ac.jp/article/99/ancient-antiviral-response-could-help-treat-cancer

By stimulating a patient’s immune system, a drug already in use to treat a blood disorder can thwart the growth of a variety of solid tumors, finds a team at Keio University[1].

The drug 5-aza-CdR is currently approved for treating a blood disorder that can lead to leukemia. It inhibits the methylation of DNA, preventing enzymes from chemically modifying genomic DNA. Such modifications can greatly alter the expression of genes that control a variety of critical cellular functions, including cell growth and survival.

Some studies have shown that methylation inhibitors such as 5-aza-CdR could be used to treat other cancers. These effects have generally been attributed to the drugs reactivating tumor-suppressor genes, but the actual mechanism remains poorly understood.

Yoshimasa Saito and his co-workers at Keio University set about figuring out how the drugs work. They began by assessing the effects of 5-aza-CdR on a mouse model of intestinal cancer. The team found that the drug cut the number of tumors that formed by roughly a third and that animals that received the drug tended to have smaller tumors than those that did not.

Having demonstrated that 5-aza-CdR can act on such cancers, the researchers then cultured cells derived from mouse intestinal tumors under conditions that promote the formation of three-dimensional ‘organoids’.

“Organoids are budding, cyst-like structures that closely recapitulate the properties of the original tumors,” explains Saito, “This makes them a powerful tool for studying how cancers respond to treatment.”

The researchers found that 5-aza-CdR strongly inhibited the growth of tumor-derived organoids and were minimally toxic to healthy intestinal cells.

Delving deeper, Saito’s team looked at which genes were turned off and on by this treatment and noticed a striking pattern. “Our findings indicated that DNA demethylation suppresses the proliferation of intestinal tumor organoids by inducing an anti-viral response,” says Saito. He and his colleagues suggest that the methylation inhibitors are somehow reactivating endogenous retroviruses — ancient viral DNA sequences that have accumulated over evolutionary history and now lie dormant throughout the genome. This initial antiviral response leads to immune activation and the shutting down of tumor proliferation.

“These findings represent a major shift in our understanding of the anti-tumor mechanisms of DNA demethylating agents,” says Saito.

The team believes the strategy could be effective for treating other cancers, and it has already obtained promising results with organoids derived from challenging tumors such as cholangiosarcoma and pancreatic cancer. “We are trying to develop a personalized therapy for refractory cancers,” says Saito.

Digital 3D-fabrication technology for nursing and healthcare
Innovative 3D-printed ‘caring-tools’ to enhance the quality of life of elderly people

https://research-highlights.keio.ac.jp/article/101/digital-3d-fabrication-technology-for-nursing-and-healthcare

3D printing technology has important medical applications, such as manufacturing prosthetic parts, implants, and models of human organs. Here, researchers at Keio University in Tokyo describe the potentially important role of 3D printing in nursing and long-term care for the elderly. Given Japan’s rapidly ageing society, demand for terminal care in hospitals or care facilities will exceed capacity in the near future. Furthermore, there are insufficient visiting nurses to provide in-house care. Therefore, strengthening in-house care is an urgent task for healthcare of the elderly. The introduction of information technology (IT) is an essential strategy from both aspects of work efficiency and providing high quality care.

Specifically, Shoko Miyagawa and colleagues at Keio University noticed the increased availability of 3D printers in self-help community centers throughout Japan. Based on interactions with nurses, medical practitioners, engineers and material designers, Miyagawa and her collaborators established a benchmark for specific digitally fabricated objects needed by patients and classified them into three types.

Firstly, are self-help devices enabling individuals to carry out specific tasks. For example, someone with paralyzed fingers who is unable to pinch, is assisted by a customized 3D-printed penholder for signing important documents.

Second, ‘caring tools’ facilitate interaction between care-givers and care-receivers. For instance, cutting out plasters in fun shapes — such as animals — with a laser cutter helps patients overcome negative perception of surgical tape.

Third, Miyagawa and colleagues identified educational objects as tools to learn how to perform therapy actions. For example, a 3D-printed semi-transparent cranial model can be used for practicing the insertion of a tube for vacuuming phlegm from a patient’s throat with light-emitting diodes acting as guides to follow its position inside the model. The researchers also addressed the question of safety, as the proposed 3D-printed objects must be washable and not produce skin irritation. Another important aspect of the research project of the Keio scientists is an assessment of the usage level of the objects. To this end, the researchers are currently developing an ‘internet-of-things’ sensing system: a data logger that can collect information about an object’s use for one month.

Having established the relevance of 3D printing techniques for improving the quality of life and the independence of elderly people, Miyagawa and colleagues conclude that, “in order to make digital fabrication more useful it is necessary to further reduce the cost of introduction and operation and to develop technologies to do so.”

Websites
Keio University
https://www.keio.ac.jp/en/

Keio Research Highlights
https://research-highlights.keio.ac.jp/

About Keio University
Keio University is a private, comprehensive university with six major campuses in the Greater Tokyo area along with a number of affiliated academic institutions. Keio prides itself on educational and research excellence in a wide range of fields and its state-of-the-art university hospital.

Keio is Japan’s first modern institution of higher learning, founded in 1858. Over the last century and a half, it has evolved into and continues to maintain its status as a leading university in Japan through its ongoing commitment to producing leaders of the future. Founder Yukichi Fukuzawa, a highly respected educator and one of the most important intellectuals of modern Japan, aspired for Keio to be a pioneer of new discoveries and contribute to society through learning.

Office of Research Development and Sponsored Projects, Keio University (JAPAN), +81 9065213797, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.